Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Xiatianwu Injection** is a Chinese prescription botanical injection prepared as a sterile aqueous extract of *Corydalis decumbens* rhizome, known in Chinese medicine as Xia Tian Wu. It is administered intramuscularly and is marketed in China for promoting circulation and relieving pain, including hypertensive hemiplegia, poliomyelitis sequelae, sciatica, rheumatic joint pain, and traumatic injury. The product is a chemically complex botanical preparation rather than isolated protopine; the labeled 2 mL presentation contains 0.4 mg protopine, while pharmacokinetic analyses have identified numerous alkaloids, including protopine, tetrahydropalmatine, and bicuculline. A prospective ChiCTR study is evaluating its use as a neuroblockade analgesic intervention for herpes zoster. ([ypk.39.net](https://ypk.39.net/756974/manual))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiatianwu Injection.